Monitor the company's cash burn rate and future drawdowns under the facility, as continued reliance on debt for general corporate purposes may signal funding needs ahead of key clinical milestones.
Price Chart
Executive Summary
TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview Holdings One LLC for general corporate purposes. The draw is a routine incremental borrowing under a previously established facility and does not represent new debt terms or a change in financial condition.
Key Facts
- On October 9, 2026, TuHURA borrowed an additional $650,000 under its existing $50 million revolving credit facility.
- The facility matures on April 21, 2031, and the funds are for general corporate purposes.
- The loan agreement was originally entered into on April 21, 2026, with Parkview Holdings One LLC as lender.
Financial Impact
Incremental draw of $650,000 under a $50 million revolving credit facility; no change to total facility size or terms.
Risk Factors
- Potential inability to satisfy conditions for future drawdowns or maintain compliance with loan covenants.
- Conflict of interest risk as lender is an affiliate of the company's largest stockholder.
- Funds available may be insufficient to fully fund operations and development programs.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-424228 |
| Document: 0001193125-26-424228-index-headers.html | 0001193125-26-424228 |
| Document: 0001193125-26-424228-index.html | 0001193125-26-424228 |
| Document: 0001193125-26-424228.txt | 0001193125-26-424228 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 8-K | $1.78 | awaiting T+60 | — | $2.03 (+14.04%) |
Sep 24, 2026 4w ago | 8-K | $2.10 | awaiting T+60 | — | $2.03 (−3.33%) |
Sep 17, 2026 5w ago | 8-K | $2.10 | awaiting T+60 | — | $2.03 (−3.33%) |
Sep 16, 2026 5w ago | 8-K | $2.09 | awaiting T+60 | — | $2.03 (−2.87%) |
Sep 4, 2026 7w ago | 8-K | $2.12 | awaiting T+60 | — | $2.03 (−4.25%) |
Aug 19, 2026 9w ago | 8-K | $2.22 | awaiting T+60 | — | $2.03 (−8.56%) |
Aug 14, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.03 (−17.81%) |
Aug 14, 2026 10w ago | Press Release | $2.47 | awaiting T+60 | — | $2.03 (−17.81%) |
Aug 13, 2026 10w ago | 8-K | $2.47 | awaiting T+60 | — | $2.03 (−17.81%) |
Jul 29, 2026 12w ago | 8-K | $2.17 $2.18 | ▲ +0.46% | ▼ −2.00% | $2.03 (−6.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers